

# Resource Summary Report

Generated by [nidm-terms](#) on Sep 21, 2026

## Developmental Therapeutics Program

RRID:SCR\_003057

Type: Tool

### Proper Citation

Developmental Therapeutics Program (RRID:SCR\_003057)

### Resource Information

**URL:** <http://www.dtp.nci.nih.gov>

**Proper Citation:** Developmental Therapeutics Program (RRID:SCR\_003057)

**Description:** Portal for preclinical information and research materials, including web-accessible data and tools, NCI-60 Tumor Cell Line Screen, compounds in vials and plates, tumor cells, animals, and bulk drugs for investigational new drug (IND)-directed studies. DTP has been involved in the discovery or development of more than 70 percent of the anticancer therapeutics on the market today, and will continue helping the academic and private sectors to overcome various therapeutic development barriers, particularly through supporting high-risk projects and therapeutic development for rare cancers. Initially DTP made its drug discovery and development services and the results from the human tumor cell line assay publicly accessible to researchers worldwide. At first, the site offered in vitro human cell line data for a few thousand compounds and in vitro anti-HIV screening data for roughly 42,000 compounds. Today, visitors can find: \* Downloadable in vitro human tumor cell line data for some 43,500 compounds and 15,000 natural product extracts \* Results for 60,000 compounds evaluated in the yeast assay \* In vivo animal model results for 30,000 compounds \* 2-D and 3-D chemical structures for more than 200,000 compounds \* Molecular target data, including characterizations for at least 1,200 targets, plus data from multiple cDNA microarray projects In addition to browsing DTP's databases and downloading data, researchers can request individual samples or sets of compounds on 96-well plates for research, or they can submit their own compounds for consideration for screening via DTP's online submission form. Once a compound is submitted for screening, researchers can follow its progress and retrieve data using a secure web interface. The NCI has collected information on almost half a million chemical structures in the past 50 years. DTP has made this information accessible and useful for investigators through its 3-D database, a collection of three-dimensional structures for more than 200,000 drugs. Investigators use the 3-D database to screen compounds for anticancer therapeutic activity. Also available on DTP's website are 127,000 connection tables for anticancer agents. A connection table is a convenient way of depicting molecular structures without relying on drawn chemical structures. As unique lists of atoms and their connections, the connection tables can be indexed and stored in computer databases

where they can be used for patent searches, toxicology studies, and precursor searching, for example., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

**Abbreviations:** DTP

**Synonyms:** Developmental Therapeutics Program NCI/NIH

**Resource Type:** data or information resource, funding resource, portal, service resource, topical portal

**Keywords:** cell line, drug discovery, drug development, drug, treatment, therapy, biopharmaceutical, bortezomib, paclitaxel, romidepsin, eribulin, sipuleucel-t, anticancer therapeutic, compound, natural product extract, animal model, in vivo, in vitro, chemical structure, chemical, structure, anti-hiv, anticancer, molecular structure, database, chemotherapeutic agent, testing, drug synthesis, chemistry, grant, contract, information technology, molecular pharmacology, natural product, pharmaceutical, screening technology, toxicology, pharmacology, screening, FASEB list

**Related Condition:** Cancer, Tumor

**Funding:** NCI

**Availability:** THIS RESOURCE IS NO LONGER IN SERVICE

**Resource Name:** Developmental Therapeutics Program

**Resource ID:** SCR\_003057

**Alternate IDs:** nif-0000-30447

**Alternate URLs:** <https://medschool.cuanschutz.edu/colorado-cancer-center/research/research-programs/developmental-therapeutics>

**Record Creation Time:** 20220129T080216+0000

**Record Last Update:** 20260919T195010+0000

---

## Ratings and Alerts

No rating or validation information has been found for Developmental Therapeutics Program.

No alerts have been found for Developmental Therapeutics Program.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 571 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [nidm-terms](#) .

Ahmad F, et al. (2026) Systemic cyst(e)inase administration induces ferroptosis and synergizes with temozolomide in glioblastoma. *iScience*, 29(1), 114350.

Mohamed-Ezzat RA, et al. (2026) Novel indole-based scaffolds: Design, synthesis, molecular modeling, and anti-proliferative evaluation. *BMC chemistry*, 20(1).

Alshazly O, et al. (2026) Novel pyrazole-oxadiazole-chalcone/oxime hybrids as dual EGFR/VEGFR-2 inhibitors with promising anticancer potential: a comprehensive cytotoxicity evaluation, mechanistic insights and SAR analysis. *Molecular diversity*, 30(3), 4667.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. *Cancer research communications*, 5(2), 375.

Negi V, et al. (2025) Azanucleoside treatment leads to B-cell precursor acute lymphoblastic leukemia. *Blood neoplasia*, 2(4), 100161.

Bidula S, et al. (2025) Screening herbal and natural product libraries to aid discovery of novel allosteric modulators of human P2X7. *Purinergic signalling*, 21(2), 365.

Sun NY, et al. (2025) Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. *Nature communications*, 16(1), 5511.

O'Sullivan Coyne G, et al. (2025) Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas. *Cancer chemotherapy and pharmacology*, 95(1), 58.

Mi W, et al. (2025) Apoptosis regulators of the Bcl-2 family play a key role in chemoresistance of cholangiocarcinoma organoids. *International journal of cancer*, 157(8), 1694.

Sudo M, et al. (2025) Carbon-ion irradiation together with autophagy inhibition and immune checkpoint inhibitors protect against pancreatic cancer development in mouse model. *Journal of hepato-biliary-pancreatic sciences*, 32(7), 532.

Dexheimer TS, et al. (2025) Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids. *SLAS discovery : advancing life sciences R & D*, 32, 100222.

Evrard YA, et al. (2025) Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models. *Frontiers in oncology*, 15, 1571635.

Ng MY, et al. (2025) Biochemical and biophysical characterization of inositol-tetrakisphosphate 1-kinase inhibitors. *The Journal of biological chemistry*, 301(3), 108274.

T??th O, et al. (2025) Identification of new reference genes with stable expression patterns for cell cycle experiments in human leukemia cell lines. *Scientific reports*, 15(1), 1052.

Brown S, et al. (2025) G-quadruplex and i-motif DNA structures form in the promoter of the key innate immune adaptor MYD88. *Cell reports. Physical science*, 6(5).

Song Z, et al. (2025) NFKB1 as a key player in Tumor biology: from mechanisms to therapeutic implications. *Cell biology and toxicology*, 41(1), 29.

Acosta-Mercado J, et al. (2025) Evaluating Naphthalene-Modified Metallosalen Complexes as Anticancer Agents. *Journal of medicinal chemistry*, 68(14), 14300.

Zhou J, et al. (2025) The potential role of cuproptosis-related genes for therapy and immunoregulation in pan-cancer. *PloS one*, 20(7), e0324389.

Sahile HA, et al. (2025) The Parkinson's drug benztropine possesses histamine receptor 1-dependent host-directed antimicrobial activity against *Mycobacterium tuberculosis*. *npj antimicrobials and resistance*, 3(1), 70.

Teicher BA, et al. (2025) Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models. *Academia oncology*, 2(2).